Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.38 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879714 | 0.91 | BRD4 (0.43) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL17879711 | 0.86 | BRD4 (0.46) | BRD4BRD9BRD7BRD2BRDT | |
| SCHEMBL18086995 | 0.83 | BRD4 (0.43) | BRD4BRD9BRD7BRD2BRDT | |
| SCHEMBL17879721 | 0.82 | BRD4 (0.54) | BRD4 | |
| SCHEMBL15788355 | 0.79 | BRD4 (0.45) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL17879720 | 0.78 | BRD4 (0.56) | BRD4 | |
| SCHEMBL17879715 | 0.76 | BRD4 (0.41) | BRD4BRD9BRD7BRD2BRDT | |
| SCHEMBL17879716 | 0.69 | BRD4 (0.49) | BRD4BRD9BRD7 | |
| SCHEMBL19930928 | 0.67 | BRD4 (0.51) | BRD4BRD9BRD7BRD2BRDT | |
| SCHEMBL198461 | 0.66 | CSNK2A2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | BRD4 1/4885BRD9 16/4885BRD7 13/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | BRD4 2/4885BRD9 26/4885BRD7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.